CORC

浏览/检索结果: 共9条,第1-9条 帮助

已选(0)清除 条数/页:   排序方式:
Subgroup analysis of olaparib monotherapy versus chemotherapy by hormone receptor and BRCA mutation status in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD 会议论文
作者:  Senkus-Konefka, E.;  Domchek, S. M.;  Im, S. A.;  Xu, B.;  Armstrong, A.
收藏  |  浏览/下载:12/0  |  提交时间:2019/12/05
Subgroup analysis of olaparib monotherapy versus chemotherapy by hormone receptor and BRCA mutation status in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD 会议论文
EUROPEAN JOURNAL OF CANCER, 2018-04-01
作者:  Senkus-Konefka, E.;  Domchek, S. M.;  Im, S. A.;  Xu, B.;  Armstrong, A.
收藏  |  浏览/下载:16/0  |  提交时间:2020/01/03
Subgroup analysis of olaparib monotherapy versus chemotherapy by hormone receptor and BRCA mutation status in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD 期刊论文
2018, 卷号: 92, 页码: S19-S20
作者:  Senkus-Konefka, E.;  Domchek, S. M.;  Im, S. A.;  Xu, B.;  Armstrong, A.
收藏  |  浏览/下载:8/0  |  提交时间:2020/01/03
OlympiAD: Further efficacy outcomes in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician"s choice 会议论文
作者:  Runswick, S.;  Robson, M.;  Conte, P. F.;  Im, S-A.;  Senkus-Konefka, E.
收藏  |  浏览/下载:4/0  |  提交时间:2019/12/05
OlympiAD: Health-related quality of life (HRQoL) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician's choice (TPC) 期刊论文
ANNALS OF ONCOLOGY, 2017, 卷号: 28
作者:  Robson, M.;  Ruddy, K. J.;  Im, S-A.;  Senkus-Konefka, E.;  Xu, B.
收藏  |  浏览/下载:4/0  |  提交时间:2019/12/05
OlympiAD: Health-related quality of life (HRQoL) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician's cho 会议论文
ANNALS OF ONCOLOGY, 2017-09-01
作者:  Robson, M.;  Ruddy, K. J.;  Im, S-A.;  Senkus-Konefka, E.;  Xu, B.
收藏  |  浏览/下载:3/0  |  提交时间:2020/01/03
OlympiAD: Further efficacy outcomes in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician's choice 会议论文
ANNALS OF ONCOLOGY, 2017-09-01
作者:  Delaloge, S.;  Conte, P. F.;  Im, S-A.;  Senkus-Konefka, E.;  Xu, B.
收藏  |  浏览/下载:3/0  |  提交时间:2020/01/03
OlympiAD: Health-related quality of life (HRQoL) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician's cho 期刊论文
2017, 卷号: 28
作者:  Robson, M.;  Ruddy, K. J.;  Im, S-A.;  Senkus-Konefka, E.;  Xu, B.
收藏  |  浏览/下载:3/0  |  提交时间:2020/01/03
OlympiAD: Further efficacy outcomes in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician's choice 期刊论文
2017, 卷号: 28
作者:  Delaloge, S.;  Conte, P. F.;  Im, S-A.;  Senkus-Konefka, E.;  Xu, B.
收藏  |  浏览/下载:3/0  |  提交时间:2020/01/03


©版权所有 ©2017 CSpace - Powered by CSpace